Batt MM, Duffy KA, Novick AM, et al. Is postpartum depression different from depression occurring outside of the perinatal period? A review of the evidence. Focus (Am Psychiatr Publ). 2020;18:106–19.

PubMed  Google Scholar 

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013.

Zhang Q, Dai X, Li W. Comparative efficacy and acceptability of pharmacotherapies for postpartum depression: a systematic review and network meta-analysis. Front Pharmacol. 2022;13:950004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report. 2022. Accessed 09 Feb 2024.

la Torre JA, Vilagut G, Ronaldson A, et al. Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. Lancet Public Health. 2021;6:e729–38.

Article  Google Scholar 

Santomauro DF, Herrera AMM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700–12.

Article  Google Scholar 

Park LT, Zarate CA. Depression in the primary care setting. N Engl J Med. 2019;380:559–68.

Article  PubMed  PubMed Central  Google Scholar 

Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel). 2010;3:19–41.

Article  CAS  PubMed  Google Scholar 

Depression: How effective are antidepressants? Inf. Internet, Institute for Quality and Efficiency in Health Care (IQWiG); 2020.

Suryawanshi O 4th, Pajai S. A comprehensive review on postpartum depression. Cureus. 2022;14(12):e32745.

PubMed  PubMed Central  Google Scholar 

DiGregory S, Githere N, Crites K, et al. The impact of COVID-19 on postpartum depression and the responsibility of the healthcare system. Cureus. 2022;14(8):e27805.

PubMed  PubMed Central  Google Scholar 

Stewart DE, Vigod SN. Postpartum depression: pathophysiology, treatment, and emerging therapeutics. Annu Rev Med. 2019;70:183–96.

Article  CAS  PubMed  Google Scholar 

Rundgren S, Brus O, Båve U, et al. Improvement of postpartum depression and psychosis after electroconvulsive therapy: a population-based study with a matched comparison group. J Affect Disord. 2018;235:258–64.

Article  PubMed  Google Scholar 

Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017;390:480–9.

Article  CAS  PubMed  Google Scholar 

Agis-Balboa RC, Guidotti A, Pinna G. 5α-reductase type I expression is downregulated in the prefrontal cortex/Brodmann’s area 9 (BA9) of depressed patients. Psychopharmacology. 2014;231:3569–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meltzer-Brody S, Kanes SJ. Allopregnanolone in postpartum depression: role in pathophysiology and treatment. Neurobiol Stress. 2020;12:100212.

Article  PubMed  PubMed Central  Google Scholar 

Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392:1058–70.

Article  CAS  PubMed  Google Scholar 

Treatment for PPD | ZULRESSO® (brexanolone) CIV n.d. https://www.zulresso.com/treatment. Accessed 09 Feb 2024.

Clayton AH, Lasser R, Nandy I, et al. Zuranolone in major depressive disorder: results from MOUNTAIN—a phase 3, multicenter, double-blind, randomized Placebo-Controlled Trial. J Clin Psychiatry. 2023;84:22m14445. https://doi.org/10.4088/JCP.22m14445

Article  Google Scholar 

Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org. Accessed 09 Feb 2024.

Higgins J, Thomas J, Chandler J, et al editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester: John Wiley & Sons; 2019.

Google Scholar 

RevMan Web 2020. Rev Manag Web RevMan Web 2020. https://revman.cochrane.org/. Accessed 09 Feb 2024.

Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381:903–11.

Article  CAS  PubMed  Google Scholar 

Clayton AH, Lasser R, Parikh SV, et al. Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 trial. Am J Psychiatry. 2023;180:676–84.

Article  PubMed  Google Scholar 

Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiat. 2021;78(9):951–9.

Article  Google Scholar 

Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023;180:668–75.

Article  PubMed  Google Scholar 

Kato M, Nakagome K, Baba T, et al. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: a double-blind, randomized, placebo-controlled, phase 2 clinical trial. Psychiatry Clin Neurosci. 2023;77:497–509.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851–5.

Article  CAS  PubMed  Google Scholar 

Hengartner MP, Plöderl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid-Based Med. 2022;27:69–73.

Article  PubMed  Google Scholar 

Mullard A. FDA approves first oral drug for postpartum depression, but rejects it for major depressive disorder. Nat Rev Drug Discov. 2023;22(10):774.

PubMed  Google Scholar 

Frieder A, Fersh M, Hainline R, et al. Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs. 2019;33(3):265–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ashton AK, Jamerson BD, Weinstein LW, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66:96–106.

Article  PubMed  PubMed Central  Google Scholar 

Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc. 2016;91:1280–6.

Article  CAS  PubMed  Google Scholar 

Bina R. The impact of cultural factors upon postpartum depression: a literature review. Health Care Women Int. 2008;29:568–92.

Article  PubMed  Google Scholar 

Wang Z, Liu J, Shuai H, et al. Mapping global prevalence of depression among postpartum women. Transl Psychiatry. 2021;11:543.

Article  PubMed  PubMed Central  Google Scholar